TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03227094

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard OGTT
Description: Standard-OGTT Plasma glucose : 0, 30, 60, 90, 120 minutes Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.) Questionnaires CGMS training \& delivery of Jelly-Bean/75g glucose beverage

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home-based OGTT (Beverage)
Description: In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home-based OGTT (Candy)
Description: In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
Study: NCT03638362

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants consumed placebo beverage for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart cherry juice
Description: Participants consumed tart cherry juice (8 ounces; 240 mL) per day for four weeks.
Study: NCT01415973

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 ounces of cooked, 85% lean ground beef
Description: Consumed once per subject.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 grams beef protein isolate
Description: Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
Study: NCT06332183

Intervention type: GENETIC
Intervention: Presence of polymorphisms
Description: Statistical analysis of GWAS data, Genome-wide methylation pattern analysis, Integration of GWAS data and methylation data (meQTL analysis), Pathway enrichment analysis
Study: NCT02550093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 1 (Day 1).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 1 (Day 1).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Washout Period
Description: The wash-out period will be between intervention 1 and intervention 2. 13 days in length.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Washout Period
Description: The wash-out period will be between intervention 1 and intervention 2. 13 days in length.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 2 (Day 14).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 2 (Day 14).
Study: NCT00415623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg/ day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 10mg/ day
Study: NCT04312295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP-SCT program
Description: The ACP-SCT program was designed to improve nurses' knowledge and competence in discussing ACP with Chronic Kidney Disease patients.
Study: NCT02838121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclasta
Description: Aclasta once annually for 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No IV aclasta
Study: NCT03006302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.
Study: NCT02561481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: See under active arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See under placebo arm description
Study: NCT02911298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation
Study: NCT03153891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Environment
Description: the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Built Environment
Description: the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
Study: NCT04239261

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SBI
Description: Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydrolyzed gelatin 10.0 g once daily
Study: NCT03640507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine-alcohol
Description: Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidine-iodine
Description: Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
Study: NCT01545869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional carbon dioxide laser
Description: SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
Study: NCT00708591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
Study: NCT01648244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Decision Support
Description: The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year.
Study: NCT04432649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR-276
Description: The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
Study: NCT01608737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 once daily high dose for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 once daily high dose for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 once daily low dose for 24 weeks
Study: NCT03034005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 1600 ug inhaled daily for 6 weeks
Study: NCT03614741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin continuous infusion
Description: 4500 IU continuous infusion of Tinzaparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin bolus
Description: 4500 IU bolus of Tinzaparin
Study: NCT03006302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.
Study: NCT03066804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match sacubitril/valsartan
Description: Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match enalapril
Description: Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match valsartan
Description: Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
Study: NCT03332654

Intervention type: OTHER
Intervention: Determine prevalence of stress urinary incontinence
Study: NCT03006302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.
Study: NCT01888237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose of PPI
Description: Lansoprasole (30mg) 2 tab oral BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequence of drug use
Description: lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
Study: NCT02319993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIAN WANG BU XIN DAN
Description: assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suan Tzao Ren Tang
Description: assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
Study: NCT03187106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo representing standard of care
Study: NCT02637167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii
Description: The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
Study: NCT04687436

Intervention type: DEVICE
Intervention: mechanical cervical ripening
Description: mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon

Intervention type: DEVICE
Intervention: mechanical cervical ripening
Description: mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon

Intervention type: DEVICE
Intervention: mechanical cervical ripening
Description: mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon
Study: NCT01880203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aspiration in thyroid node for Molecular Cytogenetic Analysis.
Study: NCT01751204

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium ion water (250mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium ion water (125mg)
Study: NCT03006302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m\^2) will be administered IV on day 1 of Cycles 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m\^2) will be administered IV on day 1 of Cycles 1 and 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). GVAX will be administered on Day 2 of Cycles 1 and 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). GVAX will be administered on Day 2 of Cycles 1 and 2.
Study: NCT02906761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2 tablets) twice daily for 6 months
Study: NCT03187106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
Study: NCT00802139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venoferrum(iron sucrose)
Description: administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolgre (Iron acetyl-transferase)
Description: Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
Study: NCT02116296

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ToyBox-intervention
Study: NCT02624908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: canagliflozin
Description: Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
Study: NCT03936660

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intense Education Intervention
Description: Clinics provided with existing clinical care guidelines as well as a multifaceted educational intervention to support development of an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
Study: NCT02871206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluad

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Study: NCT02959229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Lactoferrin)
Description: placebo in form of distilled water
Study: NCT00968149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: one placebo chewable tablet daily at bed time for 2 weeks
Study: NCT02624908

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
Study: NCT01521052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dTMS treatment (H1 Coil)
Description: All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
Study: NCT04138316

Intervention type: DRUG
Intervention: Candesartan
Description: Treatment with Candesartan
Study: NCT04687033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
Study: NCT02135679

Intervention type: RADIATION
Intervention: Radiotherapy

Intervention type: RADIATION
Intervention: Radiotherapy

Intervention type: RADIATION
Intervention: Radiotherapy

Intervention type: RADIATION
Intervention: Radiotherapy

Intervention type: RADIATION
Intervention: Radiotherapy

Intervention type: RADIATION
Intervention: Radiotherapy